FDA Clears Alzheimer's Blood Test for Adults as Young as 40

Author profile image NeuroNext
0 comments

On 19 August 2026, the US Food and Drug Administration (FDA) cleared PrecivityAD2, a blood test developed by C2N Diagnostics to help identify Alzheimer's-associated amyloid pathology in adults aged 40 and older who are experiencing cognitive symptoms. It is the first FDA-cleared Alzheimer's blood test intended for patients as young as 40, potentially making investigations for younger-onset disease more accessible.

The test is not intended for screening healthy people or independently diagnosing Alzheimer's disease. Instead, it provides biological evidence that can help clinicians determine whether amyloid plaques, one of the characteristic pathological features of Alzheimer's, are likely to be present in the brain. Detecting amyloid pathology and establishing the cause of a patient's cognitive symptoms remain two different clinical questions.

How does the blood test work?

PrecivityAD2 uses high-resolution mass spectrometry to measure specific proteins in a blood sample. It examines the ratio of amyloid-beta 42 to amyloid-beta 40 (Aฮฒ42/40), alongside the proportion of tau217 that is phosphorylated (%p-tau217). These measurements are combined using an algorithm to generate an Amyloid Probability Score 2 (APS2), ranging from 0 to 100. The score helps clinicians assess the likelihood of brain amyloid pathology associated with Alzheimer's disease.

Traditionally, confirming brain amyloid pathology has often required positron emission tomography (PET) imaging or analysis of cerebrospinal fluid collected through a lumbar puncture. Both approaches provide valuable information, but PET imaging is expensive and not universally available, while lumbar punctures are invasive. A blood sample is considerably easier to collect and transport, potentially allowing more patients to undergo biomarker assessment without immediately requiring either procedure.


How accurate is PrecivityAD2?

In a clinical validation study involving 1,142 people with symptoms of cognitive decline, PrecivityAD2 demonstrated a positive predictive value of 97.6% for results classified as positive and a negative predictive value of 93.1% for results classified as negative. The results were compared against established reference methods, including amyloid PET imaging and cerebrospinal fluid biomarker testing.

  • 97.6% positive predictive value: Among patients receiving a positive result, 97.6% had amyloid pathology according to the reference standard.
  • 93.1% negative predictive value: Among patients receiving a negative result, 93.1% did not have amyloid pathology according to the reference standard.
  • 17.3% received a "likely positive" classification: This group had a lower positive predictive value of 77.3%, illustrating why some results still require additional investigation.

These predictive values reflect the population studied and cannot be assumed to apply equally to everyone. Their accuracy in clinical practice depends partly on how common amyloid pathology is among the patients being tested. Importantly, these measurements concern the detection of amyloid pathology, not the independent confirmation of Alzheimer's as the cause of cognitive impairment.

Earlier clinical research also supports the technology. A 2024 validation study involving 583 participants reported strong agreement between the APS2 blood-test classification and established amyloid reference methods. Subsequent independent research has examined how well the test performs in other clinical populations, providing additional evidence for its potential role in neurological diagnosis.


Why does testing from age 40 matter?

Alzheimer's disease is commonly associated with older adults, but younger-onset Alzheimer's can develop before age 65. In younger patients, memory difficulties and cognitive changes may initially prompt investigations into stress, depression, medication effects, sleep disorders or other neurological and medical conditions. Access to reliable biomarker testing can help clinicians investigate Alzheimer's pathology when the disease is suspected, rather than relying exclusively on symptom patterns.

The new clearance does not mean everyone experiencing memory problems at 40 should undergo testing. PrecivityAD2 is specifically intended for symptomatic adults undergoing professional evaluation for cognitive impairment. A thorough assessment remains essential because cognitive difficulties have numerous possible causes, including conditions that may be treatable and entirely unrelated to Alzheimer's disease.


Evidence that blood testing changes clinical decisions

Research presented at the Alzheimer's Association International Conference in July 2026 suggests that blood-based biomarker testing can substantially improve diagnostic accuracy. In a study involving 1,310 patients with mild cognitive impairment or dementia, evaluated by 165 physicians, primary care clinicians' diagnostic accuracy increased from 65% to 93% after reviewing PrecivityAD2 results.

That improvement is significant because primary care physicians are often the first professionals to investigate memory loss and cognitive decline. Giving clinicians access to reliable biological evidence could reduce diagnostic uncertainty and help determine which patients need specialist assessment, additional imaging or evaluation for disease-modifying treatment.

However, these findings do not establish that blood testing can replace neurological examinations, cognitive assessments or other investigations. They demonstrate that biomarker results can improve decisions when incorporated into a broader clinical assessment.


What does this mean for patients?

The immediate advantage is practical. A blood test may help some patients avoid unnecessary invasive investigations, reduce dependence on expensive specialist imaging and shorten the process of identifying Alzheimer's-associated pathology. Earlier identification may also help determine eligibility for treatments designed to slow disease progression in appropriately selected patients.

Identifying Alzheimer's-associated proteins in the blood is not the same as proving that Alzheimer's disease is responsible for a patient's symptoms.

A positive result does not eliminate the possibility of other neurological or medical conditions. Amyloid pathology can coexist with other causes of cognitive impairment, and a negative result does not automatically identify an alternative diagnosis. Clinical interpretation remains essential, particularly in younger patients whose symptoms may have several possible explanations.

The FDA clearance also does not mean the newly cleared version became immediately available everywhere. C2N Diagnostics indicated in August 2026 that the FDA-cleared version was expected to become available later in the year, while its existing laboratory-developed version remained available through its clinical laboratory. Availability, reimbursement and regulatory authorisation outside the United States remain separate considerations.

PrecivityAD2 is not a cure, a population screening programme or a replacement for neurological assessment. Its importance lies in making a biologically informed investigation of Alzheimer's disease potentially simpler and more accessible. Blood-based measurements of disease-associated proteins are increasingly moving from research laboratories into regulated clinical diagnostic pathways, giving physicians additional objective evidence when investigating neurological symptoms.


References